Cardiac allograft vasculopathy (CAV) remains a leading cause of graft loss in pediatric heart transplant (HTx) recipients. Adult literature suggests that aspirin (ASA) use
Cardiac allograft vasculopathy (CAV) remains a leading cause of graft loss in pediatric heart transplant (HTx) recipients. Adult literature suggests that aspirin (ASA) use
What is the impact of early ASA use on the development of CAV in pediatric #HeartTransplant recipients? This retrospective review shows early ASA use did not reduce the risk of CAV or 🫀graft loss. @laura_daddeseMD 🔗: https://t.co/FNhJ3H7Xew https://t.co/FNhJ3H7Xew - view on twitter